The Eynsham Medical Group is a research active practice and is part of the Thames Valley and South Midlands Clinical Research Network [National Institute for Health Research]. We actively enrol patients into studies looking for ways to improve health and treatments. Dr Ian Binnian acts as Principal Investigator, and practice nurses Leanda Rankin and Janice Williams are our specialist research nurses.
We work with academic and commercial institutions (such as Oxford, Southampton and Keele Universities, and Abbott Ltd pharmaceutical company) for medical research purposes. Your consent will be sought before enrolment in any study; however, if you never wish your data to be used for the purpose of research you may opt out either by clicking on the following link www.nhs.uk or by contacting the NHS Digital Contact Centre on 0300 303 5678.
Sometimes we are asked for disease-based information for research purposes, and anonymised/pseudo-anonymised population data is requested. We contribute anonymised data to CPRD (Clinical Practice Research Datalink) for public health research, Qresearch, GPES /compulsory data collection during pandemic], RCGP RSC [Royal College of General Practitioners Research Surveillance Centre].
Individual patients cannot be identified from this information, and we would not seek an individual’s consent for these purposes. Pseudo-anonymised data is provided to IQVIA for medication and disease pattern research; however, if you have chosen to opt out of your data being used for research through the National Data Opt Out, your choice will be respected and your date will not be used for research.
If you would like to take part in any of our studies or find out more about them please book a telephone consultation with our research nurses, Janice Williams or Leanda Rankin.
OPTIMISE Trial is Published
Many thanks for the 29 patients at Eynsham Medical Group that took part in this trial in Spring 2018.
The following is from Dr James Sheppard who had the trial published:
“I am pleased to say that this afternoon, the results of our OPTiMISE trial were published in JAMA. Thanks to all of your efforts, we were able to recruit 569 participants to the trial. We show that deprescribing antihypertensives is possible in up to two thirds of patients, with blood pressure remaining well controlled (150 mm Hg or less) in 86.4% of patients in the medication reduction arm and 87.7% of patients in the usual care arm after 12 weeks (i.e. no difference between groups). We hope this will provide a good rationale for longer term follow-up of this cohort + a larger trial to examine clinical endpoints in the next few years.
Please find the full paper attached. Along with my co-chief investigator, Prof Richard McManus, I would like to say a huge thank you to all of you and the staff at your practices for the hard work you put into making this trial a reality. We very much look forward to working with you again on studies in the future.